广东精诚粤衡律师事务所 关于广东宝莱特医用科技股份有限公司 可转换公司债券回售的法律意见书 广东精诚粤衡律师事务所（以下简称"本所"）接受广东宝莱特医用科 技股份有限公司（以下简称"公司"或"宝莱特"）的委托，根据《中华人 民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法 》（以下简称"《证券法》"）、《可转换公司债券管理办法》（以下简称 "《可转债管理办法》"）、《深圳证券交易所创业板股票上市规则》（以 下简称"《股票上市规则》"）、《深圳证券交易所上市公司自律监管指引 第 15 号——可转换公司债券》（以下简称"《自律监管指引第 15 号》"） 等现行有关法律、法规、规范性文件以及《广东宝莱特医用科技股份有限公 司创业板向不特定对象发行可转换公司债券募集说明书》（以下简称"《募集 说明书》"）的规定，本所律师对公司可转换公司债券回售（以下简称"本 次回售"）的相关事宜进行了审查，并出具本法律意见书。 本所律师根据本次回售所掌握的事实和公司提供的文件资料，按照现行 法律、法规的要求发表法律意见。为出具本法律意见书，本所律师对本次回 售所涉及的有关事项进行了审查，查阅了相关文件，并对有关问题 ...

在本次发行的可转换公司债券最后两个计息年度，如果公司股票在任何连续 三十个交易日的收盘价格低于当期转股价的 70%时，可转换公司债券持有人有权 将其持有的可转换公司债券全部或部分按面值加上当期应计利息的价格回售给 公司。若在上述交易日内发生过转股价格因发生送红股、转增股本、增发新股（不 包括因本次发行的可转换公司债券转股而增加的股本）、配股以及派发现金股利 等情况而调整的情形，则在调整前的交易日按调整前的转股价格和收盘价格计算， 在调整后的交易日按调整后的转股价格和收盘价格计算。如果出现转股价格向下 修正的情况，则上述"连续三十个交易日"须从转股价格调整之后的第一个交易 日起重新计算。 最后两个计息年度可转换公司债券持有人在每年回售条件首次满足后可按 上述约定条件行使回售权一次，若在首次满足回售条件而可转换公司债券持有人 未在公司届时公告的回售申报期内申报并实施回售的，该计息年度不能再行使回 售权，可转换公司债券持有人不能多次行使部分回售权。 财通证券股份有限公司 关于广东宝莱特医用科技股份有限公司 可转换公司债券回售有关事项的核查意见 财通证券股份有限公司（以下简称"财通证券"或"保荐机构"）作为广东 宝莱 ...

Group 1 - The company has a total of 397 patents as of the end of 2024, with 30 of these patents related to the nephrology medical sector [1] - The German subsidiary remains a wholly-owned subsidiary of the company, and any temporary information disclosure will be conducted in accordance with legal and regulatory requirements [1]

（编辑 袁冠琳） 证券日报网讯 宝莱特10月13日在互动平台回答投资者提问时表示，公司严格按照相关法律法规和监管 要求履行信息披露义务。根据信息披露规则，公司已在2024年年度报告中披露了各业务板块的营业收入 数据及主要子公司的经营数据。 ...

Core Viewpoint - Baolait's stock price has experienced a decline recently, with a year-to-date increase of 22.91% but a notable drop in the last 60 days of 13.46% [1] Group 1: Stock Performance - On October 13, Baolait's stock fell by 4.59%, trading at 8.10 yuan per share, with a total market capitalization of 2.143 billion yuan [1] - The stock has seen a net outflow of 2.0895 million yuan in principal funds, with large orders accounting for 20.69% of sales [1] - Over the past five trading days, the stock has decreased by 3.91%, and over the last 20 and 60 days, it has dropped by 8.37% and 13.46%, respectively [1] Group 2: Company Overview - Guangdong Baolait Medical Technology Co., Ltd. was established on June 28, 1993, and listed on July 19, 2011 [1] - The company specializes in the research, production, sales, and service of medical device products, with revenue composition: 77.51% from blood dialysis products, 21.39% from monitoring devices, and 1.10% from other products [1] - Baolait is classified under the pharmaceutical and biological industry, specifically in medical devices [1] Group 3: Financial Performance - As of June 30, Baolait reported a decrease in operating revenue to 523 million yuan, down 2.43% year-on-year, while net profit attributable to shareholders increased by 152.22% to 1.3134 million yuan [2] - The company has distributed a total of 244 million yuan in dividends since its A-share listing, with 35.1578 million yuan distributed in the last three years [3] Group 4: Shareholder Information - As of June 30, 2025, Baolait had 18,400 shareholders, a decrease of 6.12% from the previous period, with an average of 11,477 circulating shares per shareholder, an increase of 6.50% [2] - Among the top ten circulating shareholders, Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund increased its holdings by 259,800 shares, while Hua Xia Zhong Zheng 500 Index Enhanced A became a new shareholder with 1,228,900 shares [3]

证券代码：300246 证券简称：宝莱特 公告编号：2025-065 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 2025年第三季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、宝莱转债（债券代码：123065）转股期限为 2021 年 3 月 11 日至 2026 年 9 月 3 日，最新有效的转股价格为人民币 24.02 元/股。 2、2025 年第三季度，共有 210 张"宝莱转债"完成转股（票面金额共计 21,000 元人民币），合计转为 872 股"宝莱特"股票（股票代码：300246）。 3、截至2025年第三季度末，公司剩余可转换公司债券（以下简称"可转债"） 数量为2,187,537张，剩余票面总金额为218,753,700元人民币。 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司 自律监管指引第15号——可转换公司债券》的有关规定，广东宝莱特医用科技股 份有限公司（以下简称"公司"）现将2025年第三季度可转债转股及公司总股本 变化情况公告如下： ...

Core Viewpoint - Baolait's stock price has experienced fluctuations, with a year-to-date increase of 27.77% but a recent decline in the last five, twenty, and sixty trading days [2] Group 1: Stock Performance - On October 9, Baolait's stock fell by 2.09%, trading at 8.42 CNY per share, with a total market capitalization of 2.228 billion CNY [1] - The stock has seen a net outflow of 819,900 CNY in principal funds, with large orders buying 1.6688 million CNY (4.64%) and selling 2.4887 million CNY (6.93%) [1] - Year-to-date, the stock has increased by 27.77%, but it has decreased by 1.29% over the last five trading days, 3.22% over the last twenty days, and 17.29% over the last sixty days [2] Group 2: Company Overview - Baolait Medical Technology Co., Ltd. was established on June 28, 1993, and went public on July 19, 2011, focusing on the research, production, sales, and service of medical devices [2] - The company's main revenue sources are hemodialysis products (77.51%), monitoring devices (21.39%), and other products (1.10%) [2] - As of June 30, 2025, Baolait had 18,400 shareholders, a decrease of 6.12% from the previous period, with an average of 11,477 circulating shares per shareholder, an increase of 6.50% [2] Group 3: Financial Performance - For the first half of 2025, Baolait reported operating revenue of 523 million CNY, a year-on-year decrease of 2.43%, while net profit attributable to shareholders was 1.3134 million CNY, a year-on-year increase of 152.22% [2] - Since its A-share listing, Baolait has distributed a total of 244 million CNY in dividends, with 35.1578 million CNY distributed in the last three years [3] Group 4: Shareholder Information - As of June 30, 2025, the seventh largest circulating shareholder is Jinyuan Shun'an Yuanqi Flexible Allocation Mixed Fund, holding 1.6 million shares, an increase of 259,800 shares from the previous period [3] - The ninth largest circulating shareholder is Huaxia CSI 500 Index Enhanced A Fund, holding 1.2289 million shares, marking a new entry [3]

Core Viewpoint - The company Baolite has decided not to lower the conversion price of its convertible bonds, known as "Baolite Convertible Bonds," during the upcoming two-month period following the board meeting on September 30, 2025 [1] Summary by Relevant Sections - **Board Meeting Decision**: On September 30, 2025, Baolite's board of directors held the third meeting of the ninth session and approved the proposal not to lower the conversion price of the "Baolite Convertible Bonds" [1] - **Future Actions**: The company will not propose a downward adjustment to the conversion price even if the conditions for such an adjustment are triggered again within the two-month period from October 9, 2025, to December 8, 2025 [1] - **Post-Adjustment Review**: Starting from December 9, 2025, if the conditions for a downward adjustment are triggered again, the company will convene a board meeting to consider whether to exercise the right to adjust the conversion price of the "Baolite Convertible Bonds" [1]

Core Viewpoint - Baolai Technology (300246.SZ) has received a notification from Shenzhen Linyuan Investment Management Co., Ltd. regarding the reduction of its holdings in Baolai convertible bonds, indicating a significant change in the investment landscape for the company [1] Group 1 - Shenzhen Linyuan Investment Management Co., Ltd. has cumulatively reduced its holdings of Baolai convertible bonds by 219,413 units from December 20, 2021, to September 29, 2025, which represents 10.02% of the total issuance [1] - As of September 29, 2025, Shenzhen Linyuan Investment Management Co., Ltd. holds a total of 218,594 units of Baolai convertible bonds, approximately 9.98% of the total issuance [1]

Core Viewpoint - Baolai Technology (300246.SZ) has received a notification from Shenzhen Linyuan Investment Management Co., Ltd. regarding the reduction of its holdings in Baolai Convertible Bonds, indicating a significant change in the investment landscape for the company [1] Group 1 - Shenzhen Linyuan Investment Management Co., Ltd. has cumulatively reduced its holdings of Baolai Convertible Bonds by 219,413 units from December 20, 2021, to September 29, 2025, which represents 10.02% of the total issuance [1] - As of September 29, 2025, Shenzhen Linyuan Investment Management Co., Ltd. holds a total of 218,594 units of Baolai Convertible Bonds, approximately 9.98% of the total issuance [1]